ArticleNature communications2026
Sirt6 deficiency in mast cells promotes adipose fibroinflammation in obesity through galectin-3 signaling.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Obesity- and Glucose-Dependent Differential Autophagy Marker Expression in Adipose Tissues and Adipocytes.Obesity science & practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mast cells (MCs) play a key role in obesity and insulin resistance, though the mechanisms driving adipose dysfunction remain unclear. We find that Sirt6 expression in MCs decreases with obesity in both male mice and humans. Selective depletion of Sirt6 in MCs worsens inflammation, fibrosis, and metabolic dysfunction in diet-induced obesity. Adoptive transfer of MC-deficient KitW-sh/W-sh mice with Sirt6-deficient MCs leads to greater weight gain on a high-fat diet compared to transfer with wild-type MCs; however, this effect is absent when the transferred MCs lack both Sirt6 and galectin-3. Mechanistically, Sirt6 deacetylates H3K9 at the Lgals3 promoter, inhibiting galectin-3 production and protecting against M1 macrophage polarization and adipose tissue fibrosis. Single-cell RNA sequencing reveals a fibroinflammatory MC subpopulation dominating in the adipose tissue of Sirt6 knockout mice. Targeting Sirt6 activation or galectin-3 inhibition in MCs may represent a therapeutic approach for obesity-associated adipose fibroinflammation and insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.